Earnings Outlook For Biomarin Pharmaceutical
Portfolio Pulse from Benzinga Insights
Biomarin Pharmaceutical (NASDAQ:BMRN) is set to release its latest quarterly earnings report on November 1, 2023. Analysts estimate an earnings per share (EPS) of $0.22. The company's past performance shows a pattern of beating EPS estimates, which has sometimes led to an increase in share price. However, the stock has been generally negative over the last 52-week period, with shares down 3.79%.
October 31, 2023 | 5:02 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Biomarin Pharmaceutical's upcoming earnings report could potentially impact its stock price. The company has a history of beating EPS estimates, which has sometimes led to a share price increase. However, the stock has been generally negative over the last 52 weeks.
The upcoming earnings report is a significant event for Biomarin Pharmaceutical. The company's history of beating EPS estimates could potentially lead to a positive reaction in the stock price. However, the overall negative trend in the stock over the past year could also influence investor sentiment and the stock's reaction to the earnings report.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100